Alector to Participate in the Bank of America CNS Therapeutics Conference
Rhea-AI Summary
Alector (Nasdaq: ALEC) announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025 at 2:25 pm ET. A live webcast will be available on the company’s Investors > Events & Presentations page at http://investors.alector.com. A replay will be posted on the Alector website and will remain available for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – ALEC
In the Dec 2 session, ALEC declined 7.32%, reflecting a notable negative market reaction. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Conference participation | Neutral | -7.3% | Announced fireside chat at Bank of America CNS Therapeutics Conference webcast. |
| Nov 06 | Earnings and update | Neutral | +3.6% | Reported Q3 2025 results, ABC pipeline progress, cash runway and trial status. |
| Oct 21 | Phase 3 topline data | Negative | -3.0% | Phase 3 latozinemab trial failed clinical endpoint; workforce cut and trial stops. |
| Sep 16 | R&D event | Neutral | -6.8% | Announced virtual R&D event on PGRN franchise and ABC-enabled programs. |
| Aug 28 | Investor conferences | Neutral | -0.4% | Planned presentations at three September healthcare investor conferences via webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference and clinical updates have often coincided with negative 24-hour price reactions, while the latest quarterly earnings and business update saw a modest positive move.
Over the last few months, Alector has combined clinical readouts, restructuring, and investor outreach. The Oct 21, 2025 Phase 3 INFRONT‑3 topline showed no clinical benefit for latozinemab and led to workforce cuts and trial discontinuations. Q3 2025 results on Nov 6 highlighted $291.1M in cash and ongoing ABC platform development. Multiple conference and R&D events in August and September drew attention to the PGRN and ABC franchises. Today’s conference participation fits the pattern of ongoing investor communication following these strategic shifts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET.
A webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.
About Alector
Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Argot Partners (media)
David Rosen
(212) 600-1494
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com
